Adaptive's Strategic Split
Adaptive Biotechnologies Reports 30% Q2 Revenue Growth, Plans Strategic Business Separation
Anonymous
Key Points
1
Excluding $5.5 million in milestone revenue recognized in the prior-year quarter, core MRD revenue grew 49% year over year, with MRD revenue totaling $66.2 million and MRD representing 92% of total revenue in Q2.
2
Blood-based clonoSEQ testing climbed 68% year over year and 14% sequential, reaching 51% of total testing volume for the quarter, while multiple myeloma remained Adaptive’s largest indication at 44% of clinical testing volume.
3
U.S. average selling price per test rose to $1,382, with management targeting roughly $1,400 for the full year due to contract price increases in the second half, expanded coverage in diffuse large B-cell lymphoma and mantle cell lymphoma, and ongoing payer discussions.
4
Adjusted EBITDA details show MRD delivering about $9.1 million, Immune Medicine at about negative $6.3 million, and the company posting an overall roughly -$0.7 million Adjusted EBITDA, translating to a 14% margin for the period.
5
Analysts' sentiment remains positive, with a consensus Buy rating and a 12-month price target around $22.57; shares have risen roughly 38.7% year to date, signaling favorable near-term investor outlook.
Adaptive Biotechnologies posted Q2 2026 revenue of $71.6 million, up 30% year over year, and raised its full-year MRD revenue guidance to $268 million–$278 million, according to Seeking Alpha. The company also laid out plans to separate its MRD and Immune Medicine businesses to unlock shareholder value.
The MRD business — which runs the clonoSEQ blood cancer test — drove 92% of total revenue in the quarter. Core MRD revenue, stripping out a one-time $5.5 million milestone from last year, grew 49% year over year, per Guru Focus.
clonoSEQ Testing Volume Surges on Blood-Based Growth
Adaptive ran more than 36,100 clonoSEQ tests in Q2 2026. Clinical testing revenue jumped 53% year over year, driven by higher volume and a rising average selling price (ASP). The U.S. ASP climbed to $1,382 per test. Management is targeting roughly $1,400 for the full year, according to Seeking Alpha.
Blood-based clonoSEQ tests grew the fastest — up 68% year over year and 14% from the prior quarter. Blood-based tests now make up 51% of total testing volume. Multiple myeloma remained the top indication, accounting for 44% of clinical testing volume, per Guru Focus.
MRD Separation Plan and Leadership Reshuffle Take Shape
Adaptive confirmed it will separate the MRD and Immune Medicine businesses. The goal is to let each unit focus and grow on its own. Co-founder Harlan Robins will move out of his day-to-day role and into a strategic consultant position, focused on MRD research and the separation process, per Seeking Alpha.
The company also raised $340 million through a convertible note offering to strengthen its balance sheet ahead of the split. Adaptive says it remains on track to reach positive adjusted EBITDA and free cash flow for the full year 2026.
Margins Improve as MRD Offsets Immune Medicine Drag
The MRD segment produced about $9.1 million in adjusted EBITDA for the quarter. The Immune Medicine unit posted a loss of roughly $6.3 million. Combined, the company came in at about negative $0.7 million in adjusted EBITDA — a 14% margin for the period, per Guru Focus.
Expanded insurance coverage in diffuse large B-cell lymphoma and mantle cell lymphoma, plus contract price increases set for the second half of the year, are expected to push ASP higher. Ongoing payer talks could add further upside to pricing.
Analysts Lift Targets as Stock Climbs 39% Year to Date
Morgan Stanley raised its price target on Adaptive from $20.00 to $22.00, though it kept an
The consensus analyst price target sits around $22.57, with a Buy rating from most covering firms. Shares have risen roughly 38.7% year to date, reflecting growing confidence in the MRD growth story and the upcoming business separation, per Seeking Alpha.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
12
Articles
18
Reach
30
A
AnonymousAuthor
